Journal article

Priority allocation of pandemic influenza vaccines in Australia - Recommendations of 3 community juries

C Degeling, J Williams, SM Carter, R Moss, P Massey, GL Gilbert, P Shih, A Braunack-Mayer, K Crooks, D Brown, J McVernon

Vaccine | ELSEVIER SCI LTD | Published : 2021

Abstract

BACKGROUND: Pandemic planning has historically been oriented to respond to an influenza virus, with vaccination strategy being a key focus. As the current COVID-19 pandemic plays out, the Australian government is closely monitoring progress towards development of SARS-CoV2 vaccines as a definitive intervention. However, as in any pandemic, initial supply will likely be exceeded by demand due to limited manufacturing output. METHODS: We convened community juries in three Australian locations in 2019 to assess public acceptability and perceived legitimacy of influenza pandemic vaccination distribution strategies. Preparatory work included literature reviews on pandemic vaccine allocation strat..

View full abstract

Grants

Awarded by Australian Government Department of Health Office of Health Protection Approach to Market: Health


Awarded by Australian Government National Health and Medical Research Council (NHMRC)


Awarded by NHMRC Principal Research Fellowship


Funding Acknowledgements

This project was directly funded by the Australian Government Department of Health Office of Health Protection Approach to Market: Health/17-18/73536 Investigate and Model Initial Pandemic Influenza Vaccination Target Groups -extension to conduct Citizens' Juries.The Australian Partnership for Preparedness Research on Infectious Disease Emergencies is a Centre of Research Excellence funded by the Australian Government National Health and Medical Research Council (NHMRC) GNT1116530. The Centre for Research Excellence in Emerging Infectious Disease (CREID) is funded by the Australian Government National Health and Medical Research Council (NHMRC) GNT1102962.Jodie McVernon is supported by a NHMRC Principal Research Fellowship GNT1117140.